{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(1)"],"submitter":["Hwang HM"],"funding":["INNOPOLOS foundation of the Republic of Korea","Korea Research Institute of Bioscience and Biotechnology"],"pubmed_abstract":["Background
Tumor-associated (TA) autoantibodies, which are generated by the immune system upon the recognition of abnormal TA antigens, are promising biomarkers for the early detection of tumors. In order to detect autoantibody biomarkers effectively, antibody-specific epitopes in the diagnostic test should maintain the specific conformations that are as close as possible to those presenting in the body. However, when using patients' serum as a source of TA autoantibodies the characterization of the autoantibody-specific epitope is not easy due to the limited amount of patient-derived serum.Methods
To overcome these limits, we constructed a B cell hybridoma pool derived from a hepatocellular carcinoma (HCC) model HBx-transgenic mouse and characterized autoantibodies derived"],"journal":["Journal of translational medicine"],"pagination":["177"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6025833"],"repository":["biostudies-literature"],"pubmed_title":["Identification of anti-SF3B1 autoantibody as a diagnostic marker in patients with hepatocellular carcinoma."],"pmcid":["PMC6025833"],"pubmed_authors":["Yu DY","Lim KJ","Kim JY","Kwak SS","Hwang HM","Heo CK","Cho EW","Lee HJ","Lim WH","Yoo JS"],"additional_accession":[]},"is_claimable":false,"name":"Identification of anti-SF3B1 autoantibody as a diagnostic marker in patients with hepatocellular carcinoma.","description":"Background
Tumor-associated (TA) autoantibodies, which are generated by the immune system upon the recognition of abnormal TA antigens, are promising biomarkers for the early detection of tumors. In order to detect autoantibody biomarkers effectively, antibody-specific epitopes in the diagnostic test should maintain the specific conformations that are as close as possible to those presenting in the body. However, when using patients' serum as a source of TA autoantibodies the characterization of the autoantibody-specific epitope is not easy due to the limited amount of patient-derived serum.Methods
To overcome these limits, we constructed a B cell hybridoma pool derived from a hepatocellular carcinoma (HCC) model HBx-transgenic mouse and characterized autoantibodies derived","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jun","modification":"2026-05-05T20:50:30.339Z","creation":"2026-04-07T21:59:40.777Z"},"accession":"S-EPMC6025833","cross_references":{"pubmed":["29954402"],"doi":["10.1186/s12967-018-1546-z"]}}